Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 82 of 5804
-
Can stem cell vesicles save lives in severe ARDS?
Disease control Recruiting nowTo evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EVs), ExoFlo, versus placebo for the treatment of hospitalized patients with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS).
Phase: PHASE3 • Sponsor: Direct Biologics, LLC • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Triple-Target CAR T-Cells offer new hope for tough blood cancers
Disease control Recruiting nowThis phase I trial tests the safety, side effects and best infusion dose of genetically engineered cells called anti-CD19/CD20/CD22 chimeric antigen receptor (CAR) T-cells following a short course of chemotherapy with cyclophosphamide and fludarabine in treating patients with lym…
Phase: PHASE1 • Sponsor: Sumithira Vasu • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug batoclimab aims to ease muscle weakness in myasthenia gravis
Disease control OngoingThe purpose of this 4-period study is to confirm the efficacy and safety of batoclimab in participants with gMG. In Period 1, participants will be randomized 1:1:1 to receive batoclimab 680 milligrams (mg) subcutaneously (SC) once a week (QW) or 340 mg SC QW or placebo. The prima…
Phase: PHASE3 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New Three-Drug combo aims to outsmart returning myeloma
Disease control OngoingThis is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or …
Phase: PHASE3 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Heart cell therapy shows promise for duchenne MD in major trial
Disease control OngoingHOPE-3 is a two cohort, Phase 3, multi-center, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of a cell therapy called deramiocel (CAP-1002) in study participants with Duchenne muscular dystrophy (DMD) and impaired skeletal muscle f…
Phase: PHASE3 • Sponsor: Capricor Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Engineered immune cells take aim at Mesothelin-Positive tumors
Disease control TerminatedTC-510 is a novel cell therapy that consists of autologous genetically engineered T cells expressing two synthetic constructs: first, a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endog…
Phase: PHASE1, PHASE2 • Sponsor: TCR2 Therapeutics • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New stem cell mix aims to make transplants safer for blood cancer patients
Disease control OngoingThis study will evaluate the safety, tolerability, and efficacy of Orca-T, an allogeneic stem cell and T-cell immunotherapy biologic manufactured for each patient (transplant recipient) from the mobilized peripheral blood of a specific, unique donor. It is composed of purified he…
Phase: PHASE3 • Sponsor: Orca Biosystems, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New triple therapy for kids with cystic fibrosis shows promise in phase 3 trial
Disease control OngoingThe purpose of this study is to evaluate the pharmacokinetics, safety, tolerability and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants with at least 1 triple combination responsive (TCR) mutation in the cystic fibrosis transmembrane conductance …
Phase: PHASE3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Brain cell transplant shows promise for Tough-to-Treat epilepsy
Disease control Recruiting nowThis clinical trial is designed to test whether a single image-guided intracerebral administration of inhibitory nerve cells, called interneurons (NRTX-1001), into subjects with drug-resistant unilateral mesial temporal lobe epilepsy (MTLE), with or without mesial temporal sclero…
Phase: PHASE3 • Sponsor: Neurona Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug aims to keep AML away after transplant
Disease control Recruiting nowThis is a multi-center, randomized, double-blinded, placebo controlled trial.
Phase: PHASE3 • Sponsor: Priothera SAS • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Could a simple drug save kids from sepsis organ failure?
Disease control Recruiting nowThe TRIPS study is a prospective, multi-center, double-blind, adaptively randomized, placebo-controlled clinical trial of the drug anakinra for reversal of moderate to severe hyperinflammation in children with sepsis-induced multiple organ dysfunction syndrome (MODS).
Phase: PHASE2, PHASE3 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug SKB264 takes on tough breast cancer in Late-Stage trial
Disease control OngoingThe purpose of this study is to evaluate the efficacy of SKB264 in patients with unresectable locally advanced, recurrent or metastatic triple-negative breast cancer who have failed second-line or above prior standard of care
Phase: PHASE3 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Immunotherapy cocktail shows promise against tough throat cancer
Disease control OngoingThe purpose of this study is to explore the efficacy and safety of a combination of GP chemotherapy and tislelizumab in neoadjuvant therapy combined with tislelizumab in adjuvant therapy of locoregionally advanced nasopharyngeal carcinoma patients.
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for Drug-Resistant TB: shorter Pill-Only regimen tested
Disease control OngoingMultidrug-resistant tuberculosis (MDR-TB) is tuberculosis (TB) that is resistant to at least isoniazid and rifampicin, the two most important anti-TB drugs. It occurs in 3.6% of newly diagnosed TB patients in the world and 17% of patients who have been previously treated. In 2017…
Phase: PHASE2 • Sponsor: Boston University • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Womb transplant trial offers hope for women born without a uterus
Disease control Recruiting nowAbsolute Uterine Factor Infertility (AUFI) is due to congenital or surgical absence of a uterus or the presence of a nonfunctional uterus. Until 2014, the only option for women affected by Absolute Uterine Factor Infertility (AUFI) was adoption or surrogate motherhood. Uterine tr…
Phase: NA • Sponsor: John Goss • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New combo therapy hopes to fight deadly childhood brain cancers
Disease control Recruiting nowThis phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or high-grade glioma (HGG) with a genetic chang…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New shot aims to keep insulin flowing in type 1 diabetes
Disease control OngoingThe objective of DIAGNODE-3 is to evaluate the efficacy and safety of three intranodal injections of 4 μg of Diamyd also known as retogatein compared to placebo, along with oral Vitamin D supplementation, to preserve endogenous beta cell function and influence glycemic parameters…
Phase: PHASE3 • Sponsor: Diamyd Medical AB • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug targets deadly immune overreaction in rare disease
Disease control Recruiting nowHemophagocytic lymphohistiocytosis is a rare, aggressive and life-threatening syndrome of excessive immune activation. Secondary hemophagocytic lymphohistiocytosis (sHLH) is the most common form of this disease and is typically associated with several other clinical conditions (e…
Phase: PHASE2, PHASE3 • Sponsor: Electra Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New immunotherapy combo shows promise for tough lung cancer
Disease control OngoingThis study is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of Serplulimab + chemotherapy+ concurrent radiotherapy vs chemotherapy+ concurrent radiotherapy in subjects with Limited-Stage Small Cell Lung Cancer.
Phase: PHASE3 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New hope for Hard-to-Treat breast cancer: Dato-DXd takes on chemo
Disease control OngoingThis is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC in participants with locally recurrent inoperable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy.
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC